Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Invested Capital (2016 - 2025)

Heron Therapeutics' Invested Capital history spans 14 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 142.59% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $14.3 million, up 142.59%, while the annual FY2025 figure was $14.3 million, 142.59% up from the prior year.
  • Invested Capital reached $14.3 million in Q4 2025 per HRTX's latest filing, down from $14.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $196.2 million in Q1 2021 to a low of -$40.0 million in Q3 2024.
  • Average Invested Capital over 5 years is $15.3 million, with a median of -$16.6 million recorded in 2022.
  • Peak YoY movement for Invested Capital: crashed 350.32% in 2023, then surged 142.59% in 2025.
  • A 5-year view of Invested Capital shows it stood at $77.6 million in 2021, then tumbled by 82.5% to $13.6 million in 2022, then crashed by 350.32% to -$34.0 million in 2023, then grew by 0.95% to -$33.7 million in 2024, then surged by 142.59% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Invested Capital are $14.3 million (Q4 2025), $14.9 million (Q3 2025), and -$27.3 million (Q2 2025).